Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
MediciNovaEli Lilly
Last price
$1.42$1,257.03
Currency
USD
USD
$70M$1.1T
-42.20
-$0.22$29.79
0.620.45
0$6.69
00.55%
Sector
HealthHealth
Employees
650,000
Ticker
$MNOV$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $MNOV or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.